The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Optimal approach to first-line therapy in myelofibrosis
Francesco Passamonti
• 11 Jun 2022
Francesco Passamonti, MD, University of Insubria, Varese, Italy, discusses the first-line treatment of myelofibrosis (MF), commenting on the use of hematopoietic stem cell transplantation (HSCT) and JAK inhibitors like ruxolitinib and fedratinib. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
